The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro
The objective of this study was to determine the effect of alendronate on the viability of canine osteosarcoma cells and nonneoplastic canine cells. The sample population was composed of canine osteosarcoma tumor cells. Osteosarcoma cells and canine fibroblasts were maintained in culture under standard conditions. The MTT assay for cell viability was performed after 24, 48, and 72 h of incubation with alendronate (0.001 to 1000 μM) or no drug (control). Plates were set up so that each concentration and the control had a sample number of 8. The optical density (OD) of each well was measured at 540 nm using an enzyme-linked immunosorbent assay microplate reader. The percent viability was determined for each concentration and for each incubation time. After 24 h of incubation of POS (parent osteosarcoma) and HMPOS cells with alendronate, there was no significant difference in mean OD at any drug concentration when compared with control samples. A significant concentration- and time-dependent reduction in mean OD of osteosarcoma cells was observed after 48 and 72 h of incubation, with alendronate concentrations ranging from 10 to 1000 μM. The lowest percent cell viability observed in treated cells was 35%. Conversely, alendronate did not significantly affect mean OD in fibroblasts, and the lowest percent cell viability observed was 76%. Our data indicate that alendronate may have the potential to inhibit canine osteosarcoma tumor growth. It will be important to determine the clinical relevance of these in vitro findings. If similar findings are observed in vivo, use of alendronate may also be indicated as an adjuvant to existing chemotherapeutic protocols.
Key wordscanine osteosarcoma bisphosphonate alendronate
Unable to display preview. Download preview PDF.
- Dernell, W. S.; Straw, R. C.; Withrow, S. J. Tumors of the skeletal system. In: Withrow, S. J.; Straw, R. C., ed. Small animal clinical oncology. 3rd ed. Philadelphia, PA: W. B. Saunders: 2001:378–417.Google Scholar
- Fisher, J. E.; Rogers, M. J.; Halasy, J. M., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96:133–138; 1999.PubMedCrossRefGoogle Scholar
- Giuliani, N.; Pedrazzoni, M.; Negri, G., et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455–461; 1998.PubMedCrossRefGoogle Scholar
- Green, J. R. Antitumor effects of bisphosphonates. Cancer Suppl. 97:840–847; 2003.Google Scholar
- Lin, J. H.; Duggan, D. E.; Chen, I. W., et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug. Metab. Dispos. 19:375–388; 1991.Google Scholar
- O'Brien, M.; Withrow, S. J.; Straw, R. C. Recent advances in the treatment of canine appendicular osteosarcoma. Compend. Contin. Educ. Pract. Vet. 15:939–945; 1993.Google Scholar
- Stodnick, G. J.; Berg, J.; Rand, W. M., et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J. Am. Vet. Med. Assoc. 200:995–998; 1992.Google Scholar
- Tomlin, J. L.; Sturgeon, C.; Pead, M. J., et al. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet. Rec. 147:129–132; 2001.Google Scholar